Trial: 202012017

A Randomized, Double-Blind, Placebo-Controlled Phase 3 Study of Enzastaurin Added to Temozolomide During and Following Radiation Therapy in Newly Diagnosed Glioblastoma Patients Who Possess the Novel Genomic Biomarker DGM1


III (Cancer Control)

Principal Investigator

Johanns, Tanner

Disease Site

Brain and Nervous System

Learn more about this study at: